Drug Trial Radar · NCT04733183
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Aug 28, 2020
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Philogen S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Feb 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.
Conditions
- Soft Tissue Sarcoma
Interventions
DacarbazineDrug
Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
onfekafusp alfaDrug
L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 3 months.
- Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 6 months.
- Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 9 months.
- Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 12 months.
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
Hopital Jean Minjoz
Besançon, France
Institut Bergonié
Bordeaux, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Léon Bérard
Lyon, France
Institut Paoli-Calmettes
Marseille, France
Institut régional du Cancer de Montepellier - ICM Val d'Aurelle
Montpellier, France
Institut Claudius Regaud
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Helios Klinikum Bad Saarow
Bad Saarow, Germany
Helios Klinikum Berlin- Buch
Berlin, Germany
Klinik rechts der Isar, TU München
München, Germany
Münster University Hospital
Münster, Münster, Germany
IRCCS - Istituto Ortopedico Rizzoli
Bologna, Italy
IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo
Candiolo, Italy
AOU San Luigi Gonzaga
Orbassano, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Szpital Pomorski Im. PCK
Gdynia, Poland
Maria Sklodowska Curie National Research Institute of Oncology
Warsaw, Poland
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario Virgen de La Victoria
Málaga, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Spain
Hospital Universitario Donostia
San Sebastián, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.